1. Home
  2. VVR vs CTNM Comparison

VVR vs CTNM Comparison

Compare VVR & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Invesco Senior Income Trust (DE)

VVR

Invesco Senior Income Trust (DE)

HOLD

Current Price

$2.98

Market Cap

486.4M

Sector

Finance

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$11.94

Market Cap

489.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VVR
CTNM
Founded
N/A
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
486.4M
489.4M
IPO Year
1998
2024

Fundamental Metrics

Financial Performance
Metric
VVR
CTNM
Price
$2.98
$11.94
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$19.00
AVG Volume (30 Days)
945.1K
197.5K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.93
$3.72
52 Week High
$3.83
$16.33

Technical Indicators

Market Signals
Indicator
VVR
CTNM
Relative Strength Index (RSI) 42.52 42.83
Support Level $2.93 $11.82
Resistance Level $3.08 $13.40
Average True Range (ATR) 0.03 0.93
MACD -0.00 0.01
Stochastic Oscillator 20.70 32.56

Price Performance

Historical Comparison
VVR
CTNM

About VVR Invesco Senior Income Trust (DE)

Invesco Senior Income Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide a high level of current income, consistent with the preservation of capital. The company invests in a portfolio of interests in floating or variable senior loans to corporations, partnerships, and other entities which operate in a variety of industries and geographic regions.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: